Angiocrine Bioscience

Angiocrine Bioscience is a private, clinical-stage biotech leveraging a proprietary endothelial cell co-culture platform to develop 'E-CEL' cellular therapies for tissue repair and regeneration. The company, founded in 2009, appears to be in the clinical development phase, targeting significant unmet medical needs in areas like radiation injury and potentially broader organ repair. While specific pipeline details and leadership are not publicly detailed on the minimal website provided, the company's core technology suggests a focus on harnessing the instructive power of specialized endothelial cells to drive therapeutic outcomes.

Proprietary E-CEL (Endothelial Co-culture Expanded Cells) platform for developing cellular therapies that harness endothelial cell signaling to instruct tissue repair and regeneration.

Competes in the broad and competitive cell & gene therapy space, facing rivals using mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and direct gene editing. Differentiation hinges on the unique 'instructive' signaling of its engineered endothelial cell approach versus direct cell replacement strategies.